InvestorsHub Logo
Followers 9
Posts 381
Boards Moderated 0
Alias Born 06/27/2015

Re: None

Wednesday, 01/18/2017 2:14:13 AM

Wednesday, January 18, 2017 2:14:13 AM

Post# of 2104
Coorect me if i am wrong, but if the encore-lf p2b trial is succesful and they get AA then cnat wouldnt choose the option to co-commercialize emricasan for NASH cirrhosis with nvs, but simply commercialize it by themselves. But if phase 3 is required then its a no brainer and they co-commercialize with nvs.